Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 123

1.

Longitudinal analysis of healthcare costs: a case study of patients with major depressive disorder treated with duloxetine.

Cui Z, Faries DE, Shen W, Able SL, Novick D.

J Med Econ. 2013;16(5):623-32. doi: 10.3111/13696998.2013.778267. Epub 2013 Mar 5.

PMID:
23425292
2.

Trajectory analysis of healthcare costs for patients with major depressive disorder treated with high doses of duloxetine.

Cui Z, Faries DE, Zhao Y, Novick D, Liu X.

J Med Econ. 2011;14(5):662-72. doi: 10.3111/13696998.2011.611060. Epub 2011 Sep 5.

PMID:
21892857
3.

Treatment patterns associated with Duloxetine and Venlafaxine use for Major Depressive Disorder.

Ye W, Zhao Y, Robinson RL, Swindle RW.

BMC Psychiatry. 2011 Jan 31;11:19. doi: 10.1186/1471-244X-11-19.

4.

Clinical comorbidities, treatment patterns, and healthcare costs among patients with fibromyalgia newly prescribed pregabalin or duloxetine in usual care.

Gore M, Tai KS, Chandran A, Zlateva G, Leslie D.

J Med Econ. 2012;15(1):19-31. doi: 10.3111/13696998.2011.629262. Epub 2011 Oct 20.

PMID:
21970699
5.

Early discontinuation and suboptimal dosing of duloxetine treatment in patients with major depressive disorder: analysis from a US third-party payer perspective.

Cui Z, Faries DE, Gelwicks S, Novick D, Liu X.

J Med Econ. 2012;15(1):134-44. doi: 10.3111/13696998.2011.632043. Epub 2011 Nov 2.

PMID:
22014076
6.

Medication adherence and healthcare costs among patients with diabetic peripheral neuropathic pain initiating duloxetine versus pregabalin.

Zhao Y, Sun P, Watson P.

Curr Med Res Opin. 2011 Apr;27(4):785-92. doi: 10.1185/03007995.2011.554807. Epub 2011 Feb 8.

PMID:
21303196
7.

Comparison of medication adherence and healthcare costs between duloxetine and pregabalin initiators among patients with fibromyalgia.

Zhao Y, Sun P, Watson P, Mitchell B, Swindle R.

Pain Pract. 2011 May-Jun;11(3):204-16. doi: 10.1111/j.1533-2500.2010.00412.x. Epub 2010 Aug 27.

PMID:
20807351
8.

Dosing patterns for duloxetine and predictors of high-dose prescriptions in patients with major depressive disorder: analysis from a United States third-party payer perspective.

Liu X, Cui Z, Niu L, Faries DE, Ball T, Johnstone B.

Clin Ther. 2011 Nov;33(11):1726-38. doi: 10.1016/j.clinthera.2011.09.027. Epub 2011 Oct 22.

PMID:
22019345
9.

Real-world evaluation of health-care resource utilization and costs in employees with fibromyalgia treated with pregabalin or duloxetine.

Harnett J, Margolis J, Cao Z, Fowler R, Sanchez RJ, Mardekian J, Silverman SL.

Pain Pract. 2011 May-Jun;11(3):217-29. doi: 10.1111/j.1533-2500.2010.00440.x. Epub 2010 Dec 28.

PMID:
21199319
10.

Treatment adherence and persistence with duloxetine, venlafaxine XR, and escitalopram among patients with major depressive disorder and chronic pain-related diseases.

Wang J, Liu X, Mullins CD.

Curr Med Res Opin. 2011 Jul;27(7):1303-13. doi: 10.1185/03007995.2011.576663. Epub 2011 May 12.

PMID:
21561393
11.

Use of effect size to determine optimal dose of duloxetine in major depressive disorder.

Pritchett YL, Marciniak MD, Corey-Lisle PK, Berzon RA, Desaiah D, Detke MJ.

J Psychiatr Res. 2007 Apr-Jun;41(3-4):311-8. Epub 2006 Aug 28.

PMID:
16934840
12.

Duloxetine versus escitalopram and placebo: an 8-month, double-blind trial in patients with major depressive disorder.

Pigott TA, Prakash A, Arnold LM, Aaronson ST, Mallinckrodt CH, Wohlreich MM.

Curr Med Res Opin. 2007 Jun;23(6):1303-18. Epub 2007 Apr 27.

PMID:
17559729
13.

Direct medical costs and medication compliance among fibromyalgia patients: duloxetine initiators vs. pregabalin initiators.

Sun P, Peng X, Sun S, Novick D, Faries DE, Andrews JS, Wohlreich MM, Wu A.

Pain Pract. 2014 Jan;14(1):22-31. doi: 10.1111/papr.12044. Epub 2013 Mar 14.

PMID:
23489659
14.

Initial duloxetine prescription dose and treatment adherence and persistence in patients with major depressive disorder.

Liu X, Gelwicks S, Faries DE, Able SL.

Int Clin Psychopharmacol. 2010 Nov;25(6):315-22. doi: 10.1097/YIC.0b013e32833db42e.

PMID:
20706125
15.

Evaluation of healthcare resource utilization and costs in employees with pain associated with diabetic peripheral neuropathy treated with pregabalin or duloxetine.

Margolis J, Cao Z, Fowler R, Harnett J, Sanchez RJ, Mardekian J, Silverman SL.

J Med Econ. 2010;13(4):738-47. doi: 10.3111/13696998.2010.535878. Epub 2010 Nov 24.

PMID:
21091395
16.

A Markov cost-utility analysis of escitalopram and duloxetine for the treatment of major depressive disorder.

Armstrong EP, Malone DC, Erder MH.

Curr Med Res Opin. 2008 Apr;24(4):1115-21. doi: 10.1185/030079908X273309 . Epub 2008 Mar 7.

PMID:
18331669
17.

Duloxetine in the acute and long-term treatment of major depressive disorder: a placebo- and paroxetine-controlled trial.

Detke MJ, Wiltse CG, Mallinckrodt CH, McNamara RK, Demitrack MA, Bitter I.

Eur Neuropsychopharmacol. 2004 Dec;14(6):457-70.

PMID:
15589385
18.

A randomized controlled trial of duloxetine versus placebo in the treatment of nonmajor chronic depression.

Hellerstein DJ, Stewart JW, McGrath PJ, Deliyannides DA, Batchelder ST, Black SR, Withers A, O'Shea D, Chen Y.

J Clin Psychiatry. 2012 Jul;73(7):984-91. doi: 10.4088/JCP.11m07230.

PMID:
22901348
19.

A randomized, double-blind comparison of duloxetine and venlafaxine in the treatment of patients with major depressive disorder.

Perahia DG, Pritchett YL, Kajdasz DK, Bauer M, Jain R, Russell JM, Walker DJ, Spencer KA, Froud DM, Raskin J, Thase ME.

J Psychiatr Res. 2008 Jan;42(1):22-34. Epub 2007 Apr 18.

PMID:
17445831
20.

Supplemental Content

Support Center